Réf. : HematoStat.net ; 3 (2) : R56 Mascarenhas J, Kosiorek HE, Prchal JT, Rambaldi A, Berenzon D, Yacoub A, et al. A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia. Blood. 12 mai 2022;139(19):2931‑41. Résumé L’essai [...]

Réf. : HematoStat.net ; 3 (2) : R55 Dodero A, Guidetti A, Marino F, Tucci A, Barretta F, Re A, et al. Dose-adjusted EPOCH and rituximab for the treatment of double expressor and double-hit diffuse large B-cell lymphoma: impact of TP53 mutations on [...]

Réf. :HematoStat.net ; 3 (2) : R54 Ram R, Grisariu S, Shargian-Alon L, Amit O, Bar-On Y, Stepensky P, et al. Toxicity and efficacy of chimeric antigen receptor T-cell therapy in patients with diffuse large B-cell lymphoma above the age of 70 years [...]

Réf. :HematoStat.net ; 3 (2) : R53 Kuter DJ, Efraim M, Mayer J, Trněný M, McDonald V, Bird R, et al. Rilzabrutinib, an Oral BTK Inhibitor, in Immune Thrombocytopenia. N Engl J Med. 14 avr 2022;386(15):1421‑31. Résumé Dans cet essai de phase 1-2, [...]

Réf. : HematoStat.net ; 3 (2) : R52 Bachy E, Houot R, Feugier P, Bouabdallah K, Bouabdallah R, Virelizier EN, et al. Obinutuzumab plus lenalidomide in advanced, previously untreated follicular lymphoma in need of systemic therapy: a LYSA study. Blood. 14 avr 2022;139(15):2338‑46. [...]

Réf. : HematoStat.net ; 3 (2) : R51 de Tute RM, Pawlyn C, Cairns DA, Davies FE, Menzies T, Rawstron A, et al. Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and [...]

Réf. : HematoStat.net ; 3 (1) : R50 Harrison CN, Garcia JS, Somervaille TCP, Foran JM, Verstovsek S, Jamieson C, et al. Addition of Navitoclax to Ongoing Ruxolitinib Therapy for Patients With Myelofibrosis With Progression or Suboptimal Response: Phase II Safety and Efficacy. [...]

Réf. : HematoStat.net ; 3 (1) : R49 Wu Y-J, Liu H, Zeng Q-Z, Liu Y, Wang J-W, Wang W-S, et al. All-trans retinoic acid plus low-dose rituximab vs low-dose rituximab in corticosteroid-resistant or relapsed ITP. Blood. 20 janv 2022;139(3):333‑42. Résumé Cette étude [...]

Réf. :HematoStat.net ; 3 (1) : R48 Locke FL, Miklos DB, Jacobson CA, Perales M-A, Kersten M-J, Oluwole OO, et al. Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma. N Engl J Med. 17 févr 2022;386(7):640‑54. Résumé Dans l’essai ZUMA-7, 359 patients [...]

Réf. : HematoStat.net ; 3 (1) : R47 Costa LJ, Chhabra S, Medvedova E, Dholaria BR, Schmidt TM, Godby KN, et al. Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma. J Clin Oncol. 13 déc [...]